(917) 310-3371
Cologuard is a screening stool test for selected average-risk people. Discuss symptoms, family history and prior polyps before ordering. Collect the kit exactly as instructed. A positive result requires colonoscopy and is not a diagnosis by itself. Arrange the result reviewer and diagnostic referral before testing.
Cancer screening looks for disease in people who do not have symptoms. Different tests target different cancers and apply to different risk groups. A screening visit reviews your age, history, prior tests and preferences to choose an appropriate plan. Symptoms or an abnormal screening result need diagnostic assessment rather than another routine screen.
A stool DNA test such as Cologuard, a PSA blood test, low-dose CT lung screening and a multi-cancer blood test do different jobs. A positive result is not by itself a cancer diagnosis. A negative result cannot rule out all cancer. Screening can also produce false positives, unnecessary procedures and overdiagnosis, so benefits and harms should be discussed.
USPSTF recommends colorectal screening for average-risk adults ages 45–75 and individual decisions at 76–85. Its lung recommendation covers ages 50–80 with at least 20 pack-years who currently smoke or quit within 15 years. PSA screening at ages 55–69 is an individual decision under USPSTF; routine screening at 70 or older is not recommended by that guideline. Other organizations may differ, and individual risks matter.
Review previous screening, family history, smoking exposure and symptoms. The clinician explains the recommended test, alternatives, possible results and follow-up. Cologuard is intended for selected average-risk screening; a positive stool screening result requires colonoscopy. High-risk history or concerning symptoms may require a different route from a mail-in stool test.
Bring prior reports and a family cancer history. Ask for the exact collection or imaging instructions. Some stool tests need a supplied kit, while colonoscopy has separate preparation. Tell the team about blood in stool, unexplained weight loss, a persistent new symptom or a previous abnormal result rather than presenting only a request for screening.
Galleri and other multi-cancer detection tests remain distinct from established guideline screening. The current manufacturer and NCI materials reviewed do not establish FDA approval of Galleri; an advisory panel vote is not approval. Such testing does not replace recommended breast, cervical, colorectal or eligible lung screening. Severe bleeding, marked breathing difficulty or other acute symptoms need urgent care.
Before testing, agree on who will review the result and arrange diagnostic follow-up. A positive multi-cancer signal can lead to additional testing without finding cancer. A negative result does not end recommended screening or assessment of symptoms. Track referrals until the receiving practice confirms the next step.
Confirm which tests Nao actually orders or collects, where imaging or colonoscopy occurs and who manages abnormal results. Ask about the test, visit and diagnostic follow-up costs separately.
Cologuard is a stool DNA and blood screening test for appropriate average-risk adults age 45 or older. The clinician checks age, symptoms and risk before ordering; the kit is collected according to its instructions and sent to the laboratory. A positive result requires colonoscopy, while a negative result does not exclude every cancer or explain new symptoms. Confirm ordering, kit access, charges and result follow-up with the clinic.
Cologuard is an option for selected average-risk screening, not a replacement for every colonoscopy. A positive result needs a diagnostic colonoscopy. Symptoms, prior polyps or a higher-risk history may call for a different pathway even with a negative stool result. Ask which test and interval fit your history.
A positive Cologuard result is a screening finding, not a cancer diagnosis. A diagnostic colonoscopy is needed to investigate it; repeating a stool test does not settle the result. Contact the ordering clinician for the referral and follow-up plan. Many positive results have causes other than cancer, but they must not be ignored.
Check coverage for the screening consultation, the specific stool test or colonoscopy and any follow-up separately. The recommended screening pathway and whether a colonoscopy follows a positive stool test can affect billing. Confirm your exact plan's network and cost rules before arranging the service.
New symptoms need diagnostic assessment rather than only a routine screening test. Tell the clinician about bleeding, a new lump, persistent unexplained pain, bowel changes or unexplained weight loss. A negative screening result does not rule out the cause. Heavy bleeding or severe abdominal pain needs emergency department care now. Call 911 for bleeding that will not stop, fainting, severe breathing difficulty or unsafe travel. Other new or continuing symptoms need diagnostic assessment.
Start with the main cancer-screening overview for colorectal, Galleri, cervical, PSA, and lung-screening planning across the Nao network.
Compare stool-based screening and colonoscopy options with clear next-step guidance.
Review multi-cancer early-detection planning, who may consider Galleri, and what it does not replace.
Use the cervical-screening guidance for Pap smear questions, HPV co-testing context, and local women's-health clinic access.
Handle prostate-screening timing, shared-decision questions, and PSA blood-test planning through primary care.
Check low-dose CT eligibility, smoking-history thresholds, and how screening conversations can start locally.